Trial reportJournal of cardiothoracic surgery2026
Preemptive TEVAR after type I aortic dissection repair: the ERADICARE trial on aortic remodeling and one-year outcomes.
Trial report in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA persistent distal false lumen after surgery for DeBakey type I acute aortic dissection (AAD) is associated with increased risk of adverse aortic events (AAEs). This pilot randomized controlled trial aimed to evaluate whether elective thoracic endovascular aortic repair (TEVAR), performed 1–3 months after type I AAD surgery in selected high-risk patients, promotes aortic remodeling and improves clinical outcomes.
methodsThirty-two patients who underwent surgical repair for type I AAD were randomized to either elective TEVAR (n = 15) or standard conservative management (n = 17). CT angiography–based inclusion criteria were: (a) a re-entry tear in Ishimaru zones 3 or 4, and (b) a maximum descending thoracic aorta (DTA) diameter > 40 mm and/or a false lumen diameter > 20 mm. One-year follow-up included clinical assessment and CT angiography.
resultsThe TEVAR group exhibited significantly more favorable aortic remodeling than the conservative group, as demonstrated by greater reductions in total aortic diameter (zones 2–9), greater increases in true lumen diameter (zones 3–8), and greater reductions in false lumen diameter (zones 2–8). Complete false lumen thrombosis was also more frequent in the TEVAR group (zones 2–6). Clinically, the TEVAR group had significantly lower rates of dissection extension (0% vs. 29.4%; p = 0.050), rehospitalization due to complications (0% vs. 58.8%; p < 0.001), and long-term AAEs (20.0% vs. 58.8%; p = 0.026).
conclusionsIn selected high-risk patients, performing TEVAR 1–3 months after surgical repair of type I AAD may promote favorable aortic remodeling and be associated with improved one-year clinical outcomes. CLINICAL REGISTRATION NUMBER: This study is registered with ISRCTN under the title “Endovascular Repair After Aortic Dissection Type I or Conservative – Aortic Remodeling Enhancement (ERADICARE Trial),” registration number ISRCTN 11,964,494 ( https://doi.org/10.1186/ISRCTN11964494 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.